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Insight into the function of DIO2, a susceptibility gene in human osteoarthritis, as
an inducer of cartilage damage in a rat model: is there a role for chondrocyte
hypertrophy?The detection of the relevant susceptibility genes has the prom-
ise to provide insight into underlying mechanisms of the develop-
ment and progression of osteoarthritis (OA), and to point to new
therapeutic strategies1. Early genetic studies on OA have provided
evidence that several genes harbor OA susceptibility alleles
including the growth differentiation factor 5 gene (GDF5)2,3,
SMAD family member 3 (SMAD3)4, and the deiodinase iodothyro-
nine type 2 and 3 genes (DIO2 and DIO3)5,6. More recently, Arthritis
Research UK Osteoarthritis Genetics (arcOGEN), Translational
REsearch in Europe Applied Technologies for OsteoArthritis
(TREAT-OA), RAAK (Research Arthritis and Articular Cartilage),
and other consortia have identiﬁed several OA-related quantitative
trait loci by compiling genome wide association study (GWAS)
data7,8,9,10,11. Since many of the OA susceptibility genes found by
GWAS of blood cell samples are known to be involved in early skel-
etal development, the possibility that alterations in their expres-
sion or activity in the adult, and particularly in cartilage and bone
where OA manifestation occurs, was proposed12.
The subject of a recent report byNagase et al.13, theOA susceptibil-
ity gene DIO2, encodes the deiodinase type 2 protein (D2), which is
responsible for catalyzing the conversion of intracellular inactive thy-
roid hormone (T4) to its active form (T3). During normal growth plate
development, active T3 subsequently signals the terminalmaturation
of the chondrocytes leading to cell hypertrophy, degradation and
mineralization of the cartilage matrix, and bone formation14,15. DIO2
is among a number of OA susceptibility genes, including GDF5 and
DOT1L, which are active in pathways during pre- and post-natal joint
development leading to endochondral ossiﬁcation12. Such ﬁndings
have led to the notion that chondrocyte signaling events that take
place in hypertrophic chondrocyte differentiation in the growth plate
may reappear in the adult and lead to the development of OA in artic-
ular cartilage16, although this is controversial. When ﬁrst identiﬁed,
the DIO2 polymorphismwas proposed to cause a deﬁciency of DIO2
and decreased thyroid hormone availability, impacting on cartilage
matrix integrity, chondrocyte viability, and osteophyte formation5.
Subsequent functional genomic studies have shown increased DIO2
gene expression and higher levels of protein in cartilage obtained
fromOA-affected compared to healthy joints17,18. These consequences
were proposed to be due to imbalanced expression of the DIO2 risk
allele at a 30% higher rate than the reference allele in OA compared
to healthy cartilage17. Furthermore, the DIO2 susceptibility single
nucleotide polymorphisms (SNPs) showed an association with hip
joint geometry and OA susceptibility19, suggesting that variation in
local T3 bioavailability in the growth plate may contribute to subtle1063-4584/$ – see front matter  2013 Osteoarthritis Research Society International. Pu
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chanical stability of the articular cartilage in aging individuals. In the
context of skeletal development, it is of interest that Hedgehog-
inducible WD repeat and SOCS box-containing protein 1 (WSB-1)
modulates thyroid hormone activation and parathyroid hormone
related protein (PTHrP) secretion20. Altered DIO2 activity in articular
cartilage, therefore,may disrupt homeostasis by promoting hypertro-
phic chondrocyte differentiation and other adverse events that lead
eventually to OA onset or progression5,12.
In the studies of Nagase et al.13, microarray analyses of human
cartilage showed that DIO2 was expressed at levels of more than
2-fold higher in OA samples compared to healthy controls, whereas
DIO1 was not detected and DIO3 was not signiﬁcantly different.
Also, theyshowed thatDio2wasexpressedathigher levels thanother
deiodinase genes in articular cartilage of 8-week-old rats and that T3
treatment of cultured chondrocytes and cartilage explants isolated
from these rats increased the gene expression of markers associated
with chondrocyte hypertrophy and endochondral ossiﬁcation,
including alkaline phosphatase, type X collagen, osteocalcin, and
Runx2, as reported previously by others21–23. T3 also increased
the expression of several cartilage matrix-degrading proteinases
and enhanced the effects of interleukin (IL)-1a. The DIO2 gene is
known to be upregulated by the pro-inﬂammatory nuclear factor
(NF)-kB signaling pathway24, and the siRNA-mediated suppression
of DIO2 was shown to increase IL-1b-induced expression of inﬂam-
matorymediators such as cyclooxygenase2 (COX2) and IL-1b itself25.
Thus, theconsequencesof the imbalanceddeiodinaseexpressionand
activitywill likelydependupontheavailabilityofotherupstreamand
downstream signals associated with inﬂammation and mechano-
transduction. Also, discrepancies in ﬁndings of various studies may
be due to differences among species, tissue sites, and age, as well as
the models used.
The initial microarray and in vitro data presented by Nagase
et al.13 provided the rationale for generating cartilage-speciﬁc
Dio2 transgenic rats by Col2a1-driven expression of human (h)
DIO2 in a bacterial artiﬁcial chromosome (BAC) construct. Since
Dio2-deﬁcient mice display no growth plate abnormality, the se-
vere cartilage degradation due to surgically induced OA in rats
with forced transgenic expression of hDIO2 in articular cartilage
may reﬂect the pathological changes associated with upregulated
expression in certain OA patients harboring the risk allele. Further-
more, this transgenic rat model will be a useful tool for further
following up mechanisms associated with other factors involved
in chondrocyte hypertrophy and OA, including HIF-2a, which theblished by Elsevier Ltd. All rights reserved.
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reﬂecting increased anabolism in late-stage OA, such as both type
I collagen (COL1A1) and type II collagen (COL2A1) collagen genes,
observed by Nagase et al.13 and in other microarray studies of hu-
man OA cartilage26,27.
In conclusion, the ﬁndings of the study by Nagase et al.13, by an-
alyses in human and rat cartilage and in various culturemodels, take
us a step closer to understanding the potential connection between
DIO2 expression and chondrocyte hypertrophy in OA. The novel rat
model, in which Col2a1-driven Dio2 overexpression resulted in
enhanced cartilage degradation when the animals were challenged
with surgically induced post-traumatic OA, however, did not deﬁne
chondrocyte hypertrophy as the responsible event. Rather, the over-
expression of Dio2 was associated with enhanced catabolic events
consistent with the in vitro data showing that T3 induces several
proteinase genes and enhances IL-1-induced gene expression.
Whatever the precise mechanism, it is clear from this and other
studies that imbalanced deiodinase regulation and activity in artic-
ular cartilage may lead to impaired cartilage tissue homeostasis and
enhance the probability of development of osteoarthritis due to
biomechanical trauma or aging.
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